Coronavirus Disease 2019 (COVID-19) and Inflammatory Bowel DiseasePremiere Date: Friday, May 22, 2020
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, May 22, 2021
Note: Credit Is No Longer Available
|David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
|Sushila Dalal, MD
Assistant Professor of Medicine
Inflammatory Bowel Disease Center
Section of Gastroenterology, Hepatology, and Nutrition
University of Chicago Medicine
|Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Digestive Disease and Surgery
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Professor, Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
The COVID-19 pandemic created many challenges and uncertainty in our healthcare system. One component facing clinicians managing patients with inflammatory bowel disease (IBD) is whether or not to continue providing certain pharmacotherapies in patients who are at increased risk of infection because they are immunocompromised. The consensus of gastroenterologists is that decisions should be made on a case-by-case basis, but that overall, uncontrolled disease activity and inflammation present more harm to individual patients than remaining on their biologic therapy.
Dr. Rubin, Dr. Regueiro, and Dr. Dalal have been on the frontlines of the pandemic and have been leaders in guiding care for patients with IBD based on current evidence and experience. This CMEOCast podcast is a featured excerpt from the broader virtual symposium Ulcerative Colitis in the 21st Century: Incorporating Guidelines and Real-World Evidence in Practice to Enhance Patient-Centered Care presented to assist health care providers in optimizing the management of patients with IBD during the COVID-19 pandemic.
At the end of this CE activity, participants should be able to:
- Apply expert recommendations for the management of IBD during the COVID-19 pandemic.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physicians, PAs, and nurse practitioners
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
Note to PAs: PAs may claim a maximum of .50 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME or a recognized state medical society.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Arena Pharmaceuticals, Inc.; Biomica; Bristol-Myers Squibb Company; Dizal Pharmaceutical; Eli Lilly and Company; Ferring Pharmaceuticals Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Medtronic; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Pfizer Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and TARGET PharmaSolutions, Inc. He receives other financial or material support as a member of the Board of Trustees for the American College of Gastroenterology and Crohn's & Colitis Foundation; and as Co-founder and CFO of Cornerstones Health, Inc. (non-profit).
Dr. Dalal reports that she serves on the advisory committee for Pfizer Inc. She is on the speakers bureau for AbbVie Inc.
Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.; He is on advisory boards and a consultant for AbbVie Inc.; Allergan; Amgen Inc; Celgene Corporation; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Olga Askinazi, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).